Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

Home

LFWD

L

Lifeward Ltd. (LFWD)

NCM – Цена в реальном времени. Валюта: USD

6.43

+0.13 (2.06%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

6.49

+0.06 (0.93%)

После закрытия: Mar 27, 2026, 6:01 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Lifeward Successfully Closes on Strategic Partnership with Oramed

Lifeward Successfully Closes on Strategic Partnership with Oramed

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript

Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript

Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript

Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results

Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results

Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath to c ash f low p ositiv e Oramed s trategic t ransaction r eceives s hareholder a pproval ; Lifeward g ain s n ew o ral p rotein d elivery t echnology p latform Lifeward a lready e xecuting n ew s trategy t hrough a cquisition of p owered u pper- b ody e xoskeleton t echnology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement

Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and full year 2025 financial results before the markets open on Wednesday, March 18, 2026.

Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton

Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton

Clinic d ays offered at Shirley Ryan AbilityLab, the #1 ranked rehabilitation hospital for 35 consecutive years , with the goal of a ccelerat ing p ersonal e xoskeleton a doption S treamlined pathway from evaluation to real-world use of ReWalk for people living with spinal cord injury (SCI) HUDSON, Mass. and CHICAGO, March 02, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Видео

No Data

There is no data to display

Пресс-релизы

Lifeward Successfully Closes on Strategic Partnership with Oramed

Lifeward Successfully Closes on Strategic Partnership with Oramed

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results

18.03.2026

Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results

Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath to c ash f low p ositiv e Oramed s trategic t ransaction r eceives s hareholder a pproval ; Lifeward g ain s n ew o ral p rotein d elivery t echnology p latform Lifeward a lready e xecuting n ew s trategy t hrough a cquisition of p owered u pper- b ody e xoskeleton t echnology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement

Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.